Shares of Evogene Ltd. (NASDAQ:EVGN - Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $5.17 and traded as low as $2.31. Evogene shares last traded at $2.40, with a volume of 28,936 shares changing hands.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on EVGN. Lake Street Capital decreased their price objective on shares of Evogene from $30.00 to $12.00 and set a "buy" rating for the company in a research report on Friday, August 23rd. StockNews.com assumed coverage on Evogene in a report on Friday. They issued a "sell" rating for the company.
Check Out Our Latest Research Report on EVGN
Evogene Price Performance
The company's 50 day moving average price is $2.96 and its two-hundred day moving average price is $5.17. The stock has a market capitalization of $100.15 million, a PE ratio of -5.63 and a beta of 1.40.
Evogene (NASDAQ:EVGN - Get Free Report) last released its quarterly earnings data on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.94). The company had revenue of $0.91 million for the quarter. Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%.
Institutional Trading of Evogene
A hedge fund recently raised its stake in Evogene stock. BNP Paribas Financial Markets raised its position in shares of Evogene Ltd. (NASDAQ:EVGN - Free Report) by 30.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 91,400 shares of the biotechnology company's stock after buying an additional 21,500 shares during the period. BNP Paribas Financial Markets owned about 0.22% of Evogene worth $69,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 10.40% of the company's stock.
About Evogene
(
Get Free Report)
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Further Reading
Before you consider Evogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evogene wasn't on the list.
While Evogene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
